REPLIGEN CORP (RGEN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US7599161095
REPLIGEN CORP financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 738.26 m USD |
| Gross profit | 386.25 m USD |
| Operating income | 55.17 m USD |
| EBIT | 83.90 m USD |
| Net income | 48.89 m USD |
| Diluted EPS – continuing operations | 0.86 USD |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About REPLIGEN CORP
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
More stocks
- Hikari Tsushin Inc (9435.T)
- Sime Darby Plantation Bhd (5285.KL)
- Shimano Inc (7309.T)
- SSAB AB (SSAB A.ST)
- Groep Brussel Lambert NV (GBLB.BR)
- Edison SpA (EDNR.MI)
- Harmony Gold Mining Company Ltd (HAR.JO)
- RAMBUS INC (RMBS)
- Sasol Ltd (SOL.JO)
- Vaxcyte, Inc. (PCVX)
- Qorvo, Inc. (QRVO)
- China Shipbuilding Industry Group Power Co Ltd (600482.SS)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.